

## Nasal polyposis in patients with asthma and allergic rhinitis

A AHMADIAFSHAR<sup>1,2</sup>, H R FARJD<sup>1</sup>, F MOEZZI<sup>1</sup>, N MOUSAVINASAB<sup>2,3</sup>

<sup>1</sup>Aayatollah Mousavi Hospital <sup>2</sup>Metabolic research center of Zanjan University of Medical Sciences and <sup>3</sup>Associate professor of medical Statistics, Medical faculty, Zanjan University of Medical Sciences, Zanjan, Iran

### Abstract

**Objective:** This study aimed to determine the prevalence of nasal polyps in patients with allergic rhinitis and with asthma, and also to assess the impact of this condition on these disorders.

**Study design:** Cross-sectional study.

**Methods:** The presence of nasal polyps was assessed by rhinoscopy and endoscopic examination.

**Results:** Nasal polyps were detected in 60 out of 250 patients (24 per cent) with documented asthma or allergic rhinitis. There was a statistically significant correlation between asthma severity and nasal polyposis prevalence ( $p = 0.007$ ), but not between allergic rhinitis severity and nasal polyposis prevalence ( $p = 0.081$ ). The prevalence of nasal polyps increased significantly with increasing patient age and rhinitis or asthma duration.

**Conclusion:** The prevalence of nasal polyps in patients with allergic rhinitis or asthma was higher than previously reported. Given this high prevalence of nasal polyposis, nasal examination and concomitant treatment of this disorder are recommended.

**Key words:** Nasal Polyps; Asthma; Allergic Rhinitis; Diagnosis

### Introduction

Nasal polyposis is a disease of the mucous membranes of the nose and paranasal sinuses, and is characterised by the protrusion of oedematous polyps from the meatus into the nasal cavity.<sup>1,2</sup> It is estimated that the condition affects 1–4 per cent of the population.<sup>3–5</sup>

Although the exact aetiology of this inflammatory disease remains unknown, it can coexist with asthma, aspirin intolerance, allergic fungal rhinosinusitis, cystic fibrosis and ciliary dyskinesia.<sup>6,7</sup>

There is some debate about the role of allergy in the pathogenesis of nasal polyps. Although some authors' findings have suggested a significant role of allergy in the pathogenesis, severity and recurrence of nasal polyposis,<sup>8–10</sup> other studies have not shown any association between allergy and nasal polyposis severity.<sup>11–13</sup> Furthermore, some studies have demonstrated a higher prevalence of nasal polyposis in non-atopic subjects than allergic subjects.<sup>4,14,15</sup> Moreover, there is conflicting evidence on the impact of nasal polyposis on the severity of allergic disorders, especially asthma.<sup>11,16,17</sup>

This study was performed to investigate the prevalence of nasal polyposis and its effect on the severity of symptoms in patients with allergic rhinitis and with asthma.

### Materials and methods

This study was carried out in the allergy clinic and ENT department of Valie Asr Hospital, Zanjan University of Medical Sciences, Zanjan, Iran, between December 2007 and July 2008. It was approved by the ethics committee of Zanjan University of Medical Sciences. Patients with allergic rhinitis or asthma were consecutively enrolled in the study.

The diagnosis of asthma was made based on clinical history, clinical findings and pulmonary function test results. Patients were divided into three groups according to the Global Initiative for Asthma organisation's categories of intermittent, mild persistent, and moderate and severe persistent asthma.<sup>18</sup>

Allergic rhinitis was diagnosed on the basis of clinical history, symptoms and the presence of at least one positive skin test result (Stallerger; Stalerpoint, Paris, France) for a common allergen. All patients had persistent symptoms. Allergic rhinitis severity was classified on the basis of the Allergic Rhinitis and its Impact on Asthma organisation's categories of mild allergic rhinitis and moderate to severe allergic rhinitis.<sup>19</sup>

We excluded from the study any patients with other chronic inflammatory conditions, cystic fibrosis or mucociliary disorders, and those who had received systemic corticosteroid therapy for more than two weeks.

Patients who had symptoms of both rhinitis and asthma were also excluded.

After giving informed consent, all subjects were referred to an ENT specialist. Nasal polyps were identified by anterior rhinoscopy and confirmed by endoscopic examination of the nose. Information about each patient was compiled using questionnaires.

Data were analysed using the Statistical Package for the Social Sciences software program. The chi-square test was used for parametric data and the Mann–Whitney *U* test for non-parametric data. A *p* value of less than 0.05 was considered statistically significant.

**Results and analysis**

Two hundred and fifty patients (141 females and 109 males) with either allergic rhinitis (144 individuals) or asthma (106 individuals), with a mean age ± standard deviation of 29.4 ± 14 years, were consecutively recruited into the study.

Nasal polyps were detected in 60 patients (24 per cent); they were found in 22.9 per cent of the allergic rhinitis patients and 25.4 per cent of the asthmatic patients. Nasal polyposis was detected on the right side, left side and bilaterally in 19, 16 and 25 patients, respectively.

There was no statistically significant difference in the prevalence of nasal polyposis among patients with asthma versus allergic rhinitis (*p* = 0.65). Moreover, there was no statistically significant difference in the prevalence of nasal polyps in male versus female patients (*p* = 0.8) (Table I). However, there was a significant association between patient age and nasal polyposis prevalence (*p* = 0.001) (Table I). In addition, the duration of allergic rhinitis or asthma was significantly greater in patients with nasal polyposis than in those without nasal polyposis (Table I).

An increased prevalence of nasal polyposis was associated with an increased asthma severity (Table II). However, there was no association between nasal polyposis prevalence and allergic rhinitis severity (Table III).

Patients with allergic rhinitis had at least one positive skin prick test result, from a test battery involving 16

**TABLE II**  
NASAL POLYPOSIS PREVALENCE BY ASTHMA SEVERITY STAGE

Stage*	NP? (pts; <i>n</i> (%))		All ( <i>n</i> )	<i>p</i>
	Yes	No		
1	5 (18.5)	43 (54.43)	48	0.007
2	10 (37.13)	21 (26.58)	31	
3 or 4	12 (44.44)	15 (18.98)	27	
All	27 (100)	79 (100)	106	

\*From Global Initiative for Asthma guidelines: stage 1 = intermittent; stage 2 = mild persistent; stage 3 = moderate persistent; stage 4 = severe persistent. NP = nasal polyposis; pts = patients

common aeroallergens including grass, weeds, trees, mites, moulds, cats, cockroaches and feather. However, there was no significant association between nasal polyposis prevalence and skin prick test results.

Four (3.5 per cent) of the asthmatic patients with nasal polyps had anti-inflammatory drug sensitivity, and were categorised as stage three or four (i.e. moderate persistent or severe persistent) according to the Global Initiative for Asthma guidelines.

The identification of nasal polyps was based on direct observation. The severity of nasal polyposis was not assessed.

**Discussion**

In the present study, a high prevalence of nasal polyposis was reported in patients with either allergic rhinitis or asthma; about one-quarter of these patients had nasal polyps, a much greater proportion than previously reported. A study in a Greek population reported a nasal polyposis prevalence of 4 per cent.<sup>14</sup> Another study in Rhode Island, USA, reported a nasal polyposis prevalence of 6.7 per cent in asthmatic patients and 2.2 per cent in rhinitis patients.<sup>4</sup> Another study<sup>20</sup> reported a higher prevalence of nasal polyposis in asthmatic patients (10 per cent), while our study found a higher prevalence still (25.4 per cent). These differences might be due to environmental or ethnic variations.

**TABLE I**  
PATIENT CHARACTERISTICS

Parameter	Total	NP	No NP	<i>p</i>
Age ( <i>n</i> (%))				0.0001
– ≤10 y	34 (100)	1 (2.1)	33 (97.9)	
– 11–19 y	33 (100)	0 (0)	33 (100)	
– 20–29 y	58 (100)	12 (20.7)	46 (79.3)	
– 30–39 y	59 (100)	20 (33.9)	39 (66.1)	
– ≥40 y	66 (100)	27 (40.9)	39 (59.1)	
Gender ( <i>n</i> )				0.8
– Male	109	27	82	
– Female	141	33	108	
Disease durm (y)				0.025
– Median	5.8	7.1	5.5	
– Mean (SD)	5 (3.7)	6 (4.6)	5 (3.3)	

NP = nasal polyposis present; y = years; durm = duration; SD = standard deviation

TABLE III  
NASAL POLYPOSIS PREVALENCE BY ALLERGIC RHINITIS SEVERITY

Severity	NP? (pts; n (%))		All	p
	Yes	No		
Mild	21 (63.63)	73 (65.76)	94 (65.27)	0.081
Mod to severe	12 (36.36)	38 (34.23)	50 (34.72)	
All	33 (100)	111 (100)	144 (100)	

NP = nasal polyposis; pts = patients; Mod = moderate

The male-to-female ratio of nasal polyposis sufferers was approximately equal in our study. This is similar to Klossek and colleagues' findings.<sup>5</sup> However, other studies have shown a male preponderance.<sup>21,22</sup>

Allergic rhinitis was diagnosed on the basis of itching of the nose, rhinorrhoea, sneezing occasionally with stuffiness, and a positive skin prick test. Some of these symptoms are similar to those of nasal polyposis. However, we did not find any association between allergic rhinitis severity and nasal polyposis prevalence.

- The observed prevalence of nasal polyposis in asthma and allergic rhinitis patients was higher than in previous reports
- Nasal polyposis prevalence correlated significantly with asthma severity
- Nasal polyposis prevalence increased with age and disease duration

Our study found a significant correlation between nasal polyposis prevalence and asthma severity. Some previous studies have also found increased asthma severity in the presence of nasal polyps.<sup>17,23</sup> There is some evidence to support this association. The number of mast cells and the histamine content of polyps are much higher than in other tissues. Arachidonic acid generated mediators and cytokines such as interleukins (ILs) 5, 6, 8, 9 and 17A are also found in polyp fluid. The expression of adhesion molecules, with recruitment of eosinophils and derivatives such as eosinophilic cationic protein, is also abundant. These patients suffer from an altered breathing pattern and preferential mouth breathing concomitant with post-nasal drip. These events could lead to a consistent inflammatory reaction in the upper and lower respiratory tracts.<sup>20,24–26</sup> Eosinophilia seems to be the most important feature of nasal polyps. Some evidence indicates that the colonisation of *Staphylococcus aureus* superantigen in polyp tissue induces IL5 and local immunoglobulin E production; these products amplify eosinophilic inflammation. However, these changes are similar in atopic and non-atopic patients.<sup>27–30</sup> All of these mechanisms could explain the severity of symptoms in asthmatic patients in the presence of nasal polyposis.

Some evidence also supports the role of allergens in the pathogenesis of nasal polyps, especially indoor

allergens.<sup>8,10,31</sup> However, we found no differences in skin prick test allergen positivity, comparing allergic rhinitis patients with and without nasal polyps. This result was similar to our previous study on allergens in the same region.<sup>32</sup>

In the current study, the prevalence of nasal polyposis increased with patient age and disease duration, similar to previous studies.<sup>5,14</sup> This indicates that the persistence of reactions in the respiratory tract may increase the chance of polyp development.

Several patients in our study were aspirin-hypersensitive and were classified as having either moderate or severe persistent asthma according to the Global Initiative for Asthma guidelines. This was similar to a study by Ceylan *et al.*<sup>17</sup> Aspirin hypersensitivity is thought to be a risk factor for asthma severity.

## Conclusion

We found a high prevalence of nasal polyps in our asthma and allergic rhinitis patients. Therefore, nasal polyposis should be considered a common disorder, and a comorbid factor, in these patients. Nasal examination, and appropriate management of nasal polyposis when present, is recommended in patients with asthma or allergic rhinitis.

## Acknowledgement

This study was part of the graduate thesis of Dr Hamid Reza Farjad, and was supported by the Zanjan University of Medical Science. The authors would like to thank Drs Said Talaei and Omid Ebrahimi for their valuable help during the study, and Dr Nima Rezaei for his excellent advice in preparing the manuscript.

## References

- 1 Mygind N. Advances in the medical treatment of nasal polyps. *Allergy* 1999;**54**:12–16
- 2 Kramer M, Rasp G. Nasal polyposis: eosinophilia and interleukin-5. *Allergy* 1999;**54**:1–13
- 3 Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. *Int J Epidemiol* 1999;**28**:717–22
- 4 Settigiani GA, Chafee FH. Nasal polyps in asthma and rhinitis. A review of 6,037 patients. *J Allergy Clin Immunol* 1977;**59**:17–21
- 5 Klossek JM, Neukirch F, Pribil C, Jankowski R, Serrano E, Chanal I *et al.* Prevalence of nasal polyposis in France: a cross-sectional, case-control study. *Allergy* 2005;**60**:233–7
- 6 Bateman ND, Fahy C, Woolford TJ. Nasal polyps: still more questions than answers. *J Laryngol Otol* 2003;**117**:1–9

- 7 Mygind NL, Lund V. Intranasal corticosteroids for nasal polyposis: biological rationale, efficacy and safety. *Treat Respir Med* 2006;**5**:93–102
- 8 Kirtsreesakul V. Nasal polyps: the relationship to allergy, sino-nasal infection and histopathological type. *J Med Assoc Thai* 2004;**87**:277–82
- 9 Asero R, Bottazzi G. Nasal polyposis: a study of its association with airborne allergen hypersensitivity. *Ann Allergy Asthma Immunol* 2001;**86**:283–5
- 10 Munoz del Castillo F, Jurado-Ramos A, Fernandez-Conde BL, Soler R, Barasona MJ, Cantillo E, et al. Allergenic profile of nasal polyposis. *J Investig Allergol Clin Immunol* 2009;**19**:110–16
- 11 Erbek SS, Erbek S, Topal O, Cakmak O. The role of allergy in the severity of nasal polyposis. *Am J Rhinol* 2007;**21**:686–90
- 12 Bonfils P, Avan P, Malinvaud D. Influence of allergy on the symptoms and treatment of nasal polyposis. *Acta Otolaryngol* 2006;**126**:839–44
- 13 Bonfils P, Malinvaud D. Influence of allergy in patients with nasal polyposis after endoscopic sinus surgery. *Acta Otolaryngol* 2008;**128**:186–92
- 14 Grigoreas N, Vourdas D, Petalas K, Simeonidis G, Demeroutis I, Tsioulos I. Nasal polyposis in patients with rhinitis and asthma. *Allergy Asthma Proc* 2002;**23**:169–74
- 15 Lourenco O, Fonseca AM, Taborda-Barata L. Asthma is more frequently associated with non-allergic than allergic rhinitis in Portuguese patients. *Rhinology* 2009;**47**:207–13
- 16 Staikuniene J, Vaitkus S, Japertiene LM, Ryskiene S. Association of chronic rhinosinusitis with nasal polyps and asthma: clinical and radiological features, allergy and inflammation markers. *Medicina (Kaunas)* 2008;**44**:257–65
- 17 Ceylan E, Gencer M, San I. Nasal polyps and the severity of asthma. *Respirology* 2007;**12**:272–6
- 18 National Heart Lung and Blood Institute. *Guidelines for the Diagnosis and Management of Asthma*. Bethesda, Maryland: National Heart Lung and Blood Institute, 2007
- 19 Mullol J, Valero A, Alobid J, Bartra J, Navarro AM, Chivato T et al. Allergic Rhinitis and its Impact on Asthma update (ARIA 2008). The perspective from Spain. *J Investig Allergol Clin Immunol* 2008;**18**:327–34
- 20 Braunstahl GJ, Fokkens W. Nasal involvement in allergic asthma. *Allergy* 2003;**58**:1235–43
- 21 Collins MM, Pang YT, Loughran S, Wilson JA. Environmental risk factors and gender in nasal polyposis. *Clin Otolaryngol Allied Sci* 2002;**27**:314–17
- 22 Toledano Munoz A, Herraiz Puchol C, Navas Molinero C, Garcia Simal M, Navarro Cunchillo M, Galindo Campillo AN. Epidemiological study in patients with nasal polyposis [in Spanish]. *Acta Otorrinolaringol Esp* 2008;**59**:438–43
- 23 Bavbek S, Celik G, Ediger D, Mungan D, Sin B, Demirel YS et al. Severity and associated risk factors in adult asthma patients in Turkey. *Ann Allergy Asthma Immunol* 2000;**85**:134–9
- 24 Mygind N, Dahl R, Bachert C. Nasal polyposis, eosinophil dominated inflammation, and allergy. *Thorax* 2000;**55**(suppl 2):S79–83
- 25 Saitoh T, Kusunoki T, Yao T, Kawano K, Kojima Y, Miyahara K et al. Role of interleukin-17A in the eosinophil accumulation and mucosal remodeling in chronic rhinosinusitis with nasal polyps associated with asthma. *Int Arch Allergy Immunol* 2010;**151**:8–16
- 26 Tsicopoulos A, Shimbara A, de Nadai P, Aldewachi O, Lamblin C, Lassalle P et al. Involvement of IL-9 in the bronchial phenotype of patients with nasal polyposis. *J Allergy Clin Immunol* 2004;**113**:462–9
- 27 Bachert C, Claeys SE, Tomassen P, van Zele T, Zhang N. Rhinosinusitis and asthma: a link for asthma severity. *Curr Allergy Asthma Rep* 2010;**10**:194–201
- 28 Wise SK, Ahn CN, Schlosser RJ. Localized immunoglobulin E expression in allergic rhinitis and nasal polyposis. *Curr Opin Otolaryngol Head Neck Surg* 2009;**17**:216–22
- 29 Eghtedari F, Cheraghzadeh SR, Kashef MA, Monabati A, Kashef S. Agreement rate of skin prick test with tissue eosinophil count in patients with nasal polyps. *Iran J Allergy Asthma Immunol* 2007;**6**:89–92
- 30 Fan GK, Wang H, Takenaka H. Eosinophil infiltration and activation in nasal polyposis. *Acta Otolaryngol* 2007;**127**:521–6
- 31 Muñoz-Del-Castillo F, Jurado-Ramos A, Soler R, Fernández-Conde BL, Barasona MJ, Cantillo E et al. Fungal sensitization in nasal polyposis. *J Investig Allergol Clin Immunol* 2009;**19**:6–12
- 32 Ahmadiafshar A, Sepehri S, Mousavinasab S, Torabi SZ. Recognition and frequency determination of common allergens in allergic patients of Zanjan City by skin prick test. *Zanjan University of Medical Science Journal* 2008;**16**:45–53

Address for correspondence:  
 Dr Akefeh Ahmadiafshar,  
 Associate Professor of Pediatrics,  
 Sub-specialist in Immunology and Allergy,  
 Mousavi Hospital,  
 Zanjan University of Medical Sciences,  
 Zanjan, Iran

Fax: +98 241 4131340  
 E-mail: akefeh45@zums.ac.ir

---

Dr A Ahmadiafshar takes responsibility for the integrity of the content of the paper  
 Competing interests: None declared

---